BOSTON, Sept. 30, 2024 -- Aktis Oncology, a clinical-stage biotechnology company pioneering the discovery and development of novel targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today...
AutoGenomics announces the launch of a novel test for B-RAF mutations
News | 02. 24. 2010
AutoGenomics, a leader in providing automated, molecular testing solutions announced today that it has launched an expanded test panel to detect 17 B-RAF mutations for research use to enhance the understanding of B-RAF mutations.
© 2024 Pappas Capital, LLC. ALL RIGHTS RESERVED.